| Formulary Chapter 4: Central nervous system - Full Chapter
|
|
| Chapter Links... |
 Administration of depot antipsychotic injections during COVID-19 in stable adult patients |
| Details... |
| 04.07.01 |
Non-opioid analgesics and compound analgesic preparations |
|
|
|
|
|
|
| 04.07.01 |
Compound analgesic preparations |
|
|
Aspirin
(300mg dispersible tablets)
|
Formulary
|
For gargling - topical analgesia
|
|
|
Paracetamol
(Oral)
|
Formulary
|
Tablets
SF suspension
500mg soluble tablets - high sodium content. Only for patients with swallowing difficulties
|
UKMI Q&A: Can breastfeeding mothers take paracetamol?
|
Paracetamol
(Suppositories)
|
Formulary
|
|
|
|
Paracetamol (Perfal®)
(Intravenous infusion)
|
Formulary
|
|
|
|
Paracetamol and codeine (Co-codamol 15/500)
(tablets and capsules)
|
Formulary
|
£££££
Limited evidence
For elderly community who would not tolerate separate ingredients and to support a step down review
|
|
|
Paracetamol and codeine (Co-codamol ®15/500)
(Effervescent tablets)
|
Formulary
|
£££££
Limited evidence
Only for patients with swallowing difficulties
For elderly community who would not tolerate separate ingredients and to support a step down review
High sodium content
Tablets and capsules more cost effective
|
|
|
Paracetamol and codeine (Co-codamol 30/500)
(Tablets and Capsules)
|
Formulary
|
Use with caution in patients over 65s
Contraindicated in children below the age of 12
Use in chronic pain only
|
|
|
Paracetamol and codeine (Co-codamol 30/500)
(Effervescent tablets)
|
Formulary
|
£££££
High sodium content
Only for use in patients with swallowing difficulties
Tablets and capsules more cost effective
For use in chronic pain
|
|
|
| .... |
| Non Formulary Items |
Aspirin (Caprin®, Nu-Seals® Aspirin)
|
Non Formulary
|
|
|
|
Aspirin and codeine (Co-codaprin®)
|
Non Formulary
|
|
|
|
Aspirin and papaveretum (Aspav®)
|
Non Formulary
|
|
|
|
Co-proxamol
|
Non Formulary
|
In line with NHS England's Guidance for CCGs: Items which should not routinely be prescribed in primary care (Dec 2017)
Click here to access guidance |
 Patient Information - Changes to co-proxamol prescribing
|
Nefopam
|
Non Formulary
|
|
|
|
Nefopam (Acupan®)
|
Non Formulary
|
|
|
|
Paracetamol (Panadol OA®)
|
Non Formulary
|
|
|
|
Paracetamol and codeine (Co-codamol® 8/500)
|
Non Formulary
|
|
|
|
Paracetamol and dihydrocodeine (Co-dydramol®)
|
Non Formulary
|
|
|
|
Paracetamol and dihydrocodeine (Remedeine®)
|
Non Formulary
|
|
|
|
Paracetamol and methionine (Pardote®)
|
Non Formulary
|
|
|
|
| |
Key |
 |
Restricted Drug |
 |
Unlicensed |
|
|
Link to adult BNF
|
|
|
Link to children's BNF
|
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
| Status |
Description |
|
All Settings
Suitable for initiation, ongoing prescribing, and discontinuation in both primary and secondary care settings. They are generally familiar, frequently used therapies that can be started within their licensed indications without specialist oversight. |
|
Specialist only
Designated for initiation, ongoing prescribing, monitoring, exclusively by a specialists either in a hospital or as part of a specialist service (to note this could be in a non-hospital setting). Primary care should neither start nor continue these treatments except as part of a specialist service. A specialist could be either a medical or non-medical prescriber. |
|
Specialist advice
Prescribers in primary care should seek advice and a recommendation from a specialists prior to initiating a medicine. Once agreed with a specialist, medicines can be initiated, prescribed and monitored in primary care without a formal shared-care agreement. |
|
Specialist initiation
Medicines in this category require a specialist to start therapy, titrate dosage, and assess initial efficacy or tolerability. Once stabilised, prescribing responsibility may transfer to primary care without the need for a formal shared-care agreement. |
|
Shared care agreement
Prescribing responsibility can be shared across health settings and between specialists and GPs only when formal shared care arrangement has been made. For example, there may be extensive and complex monitoring requirements or significant safety concerns (note would need a national policy on this to define the criteria for requiring a formal SCA), this will be produced once nationally. |
|
Do not prescribe
Not approved for routine prescribing in primary or secondary care. For example, because they are agents classified in the BNF as “not NHS” or “Drugs of Low Clinical Value”, or they are products on NICE’s “do not do” list or NHS England’s “should not routinely prescribe” list. |
|
Self Care
Not for routine prescribed in primary or secondary care unless as part of care for a long term condition. Instead, patients should be encouraged to self care with support from community pharmacy. |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
|
|
